Prentiss Christopher B 4
4 · MANNKIND CORP · Filed May 17, 2024
Insider Transaction Report
Form 4
MANNKIND CORPMNKD
Prentiss Christopher B
Chief Financial Officer
Transactions
- Award
Common Stock, $.01 Par Value
2024-05-15+103,600→ 103,600 total - Award
Common Stock, $.01 Par Value
2024-05-15+129,000→ 232,600 total - Award
Performance Restricted Stock Unit
2024-05-15+158,000→ 158,000 total→ Common Stock, $.01 Par Value (158,000 underlying)
Footnotes (4)
- [F1]Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.
- [F2]4-year vesting schedule with 1/4th of shares vesting on the first anniversary of the vesting determination date and on each anniversary thereafter until fully vested on the fourth anniversary of the vesting determination date. The vesting determination date for this grant is April 22, 2024.
- [F3]Acquired pursuant to a Restricted Stock Unit Award: 25% vests on July 15, 2025 and each yearly anniversary thereof until fully vested.
- [F4]The performance-based restricted stock unit will vest on July 15, 2027. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2024 until June 30, 2027 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.